This mutation enhances ATP affinity and reduces the ability of ATP-competitive reversible EGFR-TKI binding to EGFR tyrosine kinase domain, which results in cancer cells resistant to gefitinib and erlotinib [1]. Here, EGFR is linked to cancer.